<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04829630</url>
  </required_header>
  <id_info>
    <org_study_id>2020-064</org_study_id>
    <nct_id>NCT04829630</nct_id>
  </id_info>
  <brief_title>Immunity Persistence After Abridged Intradermal Rabies PEP</brief_title>
  <acronym>RESIST-3</acronym>
  <official_title>Immunity Persistence After Abridged Intradermal Rabies PEP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Pasteur</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut Pasteur du Cambodge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Pasteur de Madagascar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Pasteur</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      After exposure, rabies can be prevented in almost 100% of cases by the administration of&#xD;
      sufficient and timely post-exposure prophylaxis (PEP). PEP is based on wound cleansing,&#xD;
      antisepsis, administration of rabies vaccine as well as rabies immunoglobulin, if reviewed.&#xD;
      However, anti-rabies PEP remains too often out of financial and / or geographic access,&#xD;
      especially for poor and / or rural populations in endemic countries who remain the most&#xD;
      exposed to the risk of contracting rabies. Two major studies planned in Cambodia between 2014&#xD;
      and 2018 - the RESIST 0/1 clinical - epidemiological study and the RESIST-2 study on the&#xD;
      antibody response to the vaccine - provided the basis that allowed a change in international&#xD;
      recommendations on PPE. Since April 2018, the new &quot;IPC protocol&quot; of three sessions of reduced&#xD;
      double doses (0.1 mL x 2) administered intradermally (ID) over one week has replaced the&#xD;
      already very effective &quot;TRC protocol&quot; of four sessions over one month which was the reference&#xD;
      dose-sparing protocol for endemic countries until 2018. It remains to be determined whether&#xD;
      the IPC protocol (3 sessions / 1 week) confers long-term immunity equivalent to that obtained&#xD;
      after a TRC ID protocol (4 sessions / 1 month). This question is of importance to public&#xD;
      health decision-makers and clinical teams in endemic countries who would hesitate to switch&#xD;
      to the abbreviated IPC protocol.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, non-inferior clinical trial with samples for examinations&#xD;
      and vaccination booster.&#xD;
&#xD;
      To achieve this study, persons who previously received PEP and of any age (including&#xD;
      children), gender or medical condition (including pregnant women) and whichever the status of&#xD;
      the dog which bit at least 2, 5 or 10 years ago will be contacted and invited to participate&#xD;
      to the study.&#xD;
&#xD;
      This study will take place in two centers :&#xD;
&#xD;
        -  The rabies prevention center at Institut Pasteur du Cambodge&#xD;
&#xD;
        -  The rabies prevention center at Institut Pasteur de Madagascar. The study will be&#xD;
           coordinated by Institut Pasteur in Paris which will subsequently conduct the analysis in&#xD;
           collaboration with researchers at Institut Pasteur du Cambodge and Institut Pasteur de&#xD;
           Madagascar.&#xD;
&#xD;
      This study will take place in two visits :&#xD;
&#xD;
        -  the first visit (day 0) : after receiving consent from the participants, the member of&#xD;
           the investigating team will perform the blood sample, followed by a single session of&#xD;
           two intradermal doses of 0.1 mL. The investigators will also carry out measurements and&#xD;
           complete the questionnaire with the participant.&#xD;
&#xD;
        -  the second visit (day 7) : a follow-up visit will be performed by a member of the&#xD;
           investigating team who will perform a second blood sample to all the participants to the&#xD;
           study. The investigator will complete a second paper CRF with the participants to&#xD;
           document any unwanted effects which may have occurred during the seven days between the&#xD;
           inclusion visit and the follow-up visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>90 subjects in Cambodia or Madagascar who received ID PEP by 3 sessions/1 week at least two (30 subjects), five (30 subjects) or 10 years earlier (30 subjects),&#xD;
90 subjects in Cambodia or Madagascar who received ID PEP by 4 sessions/1 month at least two (30 subjects), five (30 subjects) or 10 years earlier (30 subjects),</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antibody titers measured (FAVN, RFFIT) and cellular immunity markers one week after a single session of ID rabies vaccine boosting in the two groups</measure>
    <time_frame>1 year</time_frame>
    <description>Absence of statistically significant difference between antibody titers Fluorescent Antibody Virus Neutralization test (FAVN) and Rapid Fluorescent Foci Inhibition Test (RFFIT) and cellular immunity markers one week after a single session of ID rabies vaccine boosting in persons who have received a 3 sessions/1 week vs. 4 sessions/ 1 month ID PEP at least 2, 5 or 10 years earlier.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibody titers measured by FAVN and RFFIT and immune response before a single session of ID rabies vaccine boosting in the two groups</measure>
    <time_frame>1 year</time_frame>
    <description>Equivalence of antibody titers and immune response before a single session of ID rabies vaccine boosting in persons who have received a 3 sessions/1 week vs. 4 sessions/ 1 month ID PEP at least 2, 5 or 10 years earlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody titers measured by FAVN and RFFIT in all subjects for comparison</measure>
    <time_frame>1 year</time_frame>
    <description>Equivalence of antibody titers measured using FAVN compared to the RFFIT used as reference.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Rabies</condition>
  <arm_group>
    <arm_group_label>subjects who received three vs. four ID PEP at least two, five or 10 years earlier</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>30 subjects who received three ID PEP at least two years earlier in Cambodia and Madagascar&#xD;
30 subjects who received three ID PEP at least five years earlier in Cambodia and Madagascar&#xD;
30 subjects who received three ID PEP at least 10 years earlier in Cambodia and Madagascar&#xD;
30 subjects who received four ID PEP at least two years earlier in Cambodia and Madagascar&#xD;
30 subjects who received four ID PEP at least five years earlier in Cambodia and Madagascar&#xD;
30 subjects who received four ID PEP at least 10 years earlier in Cambodia and Madagascar</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rabies vaccine</intervention_name>
    <description>day 0 : questionnaire, blood sampling and vaccine booster (a single session of two intradermal doses of 0.1 mL)&#xD;
day 7 : questionnaire and blood sampling</description>
    <arm_group_label>subjects who received three vs. four ID PEP at least two, five or 10 years earlier</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  person Identified in IP Cambodia or IP Madagascar records for having received ID PEP&#xD;
             by 4 sessions/1 month or 3 sessions/1 week at least two, five or 10 years earlier,&#xD;
             with no rabies boosting since that time;&#xD;
&#xD;
          -  person Who received information adapter to his/her age and who signed the consent form&#xD;
             (or his/her legal tutors)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  person who received Rabies vaccine booster since the earlier PEP&#xD;
&#xD;
          -  person with allergy or other severe unwanted effect at the time of the earlier PEP&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Perrine Parize, MD</last_name>
    <role>Study Director</role>
    <affiliation>Institut Pasteur</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Perrine Parize, MD</last_name>
    <phone>+ 33 1 40 61 34 36</phone>
    <email>perrine.parize@pasteur.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Herv√© BOURHY, MD</last_name>
    <email>herve.bourhy@pasteur.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Pasteur du Cambodge</name>
      <address>
        <city>Phnom Penh</city>
        <country>Cambodia</country>
      </address>
    </facility>
    <contact>
      <last_name>Sowat Ly, MD</last_name>
      <phone>(855) 23 368 036</phone>
      <email>lsowath@pasteur-kh.org</email>
    </contact>
    <contact_backup>
      <last_name>VEASNA DUONG, MD</last_name>
      <phone>+855 12207095</phone>
      <email>dveasna@pasteur-kh.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Institut Pasteur de Madagascar</name>
      <address>
        <city>Antananarivo</city>
        <zip>BP 1274</zip>
        <country>Madagascar</country>
      </address>
    </facility>
    <contact>
      <last_name>Rindra RANDREMANANA, MD</last_name>
      <email>rrandrem@pasteur.mg</email>
    </contact>
    <contact_backup>
      <last_name>Philippe DUSSART, PharmD</last_name>
      <phone>+261 20 22 412 72</phone>
      <email>pdussart@pasteur.mg</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Cambodia</country>
    <country>Madagascar</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 31, 2021</study_first_submitted>
  <study_first_submitted_qc>March 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rabies</keyword>
  <keyword>vaccine</keyword>
  <keyword>Post-exposure prophylaxis</keyword>
  <keyword>Persistent immunity</keyword>
  <keyword>Short protocol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rabies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

